2430-22-0Relevant articles and documents
Isolation of new aliphatic sulfates and sulfamate as the Daphnia kairomones inducing morphological change of a phytoplankton Scenedesmus gutwinskii
Yasumoto, Ko,Nishigami, Akinori,Aoi, Hiroaki,Tsuchihashi, Chise,Kasai, Fumie,Kusumi, Takenori,Ooi, Takashi
, p. 133 - 136 (2008)
New aliphatic sulfates and sulfamates were isolated from Daphnia pulex as the Daphnia kairomones that induced morphological defense of a freshwater phytoplankton Scenedesmus gutwinskii var. heterospina (NIES-802). Their structures were determined by spectroscopic and synthetic studies.
Method for producing a shaped catalyst body
-
Page/Page column 29-30, (2021/11/19)
Provided herein is a novel process for producing shaped catalyst bodies in which a mixture having aluminum contents of Al±0 in the range from 80 to 99.8% by weight, based on the mixture used, is used to form a specific intermetallic phase, shaped catalyst bodies obtainable by the process of the invention, a process for producing an active catalyst fixed bed including the shaped catalyst bodies provided herein, the active catalyst fixed beds and also the use of these active catalyst fixed beds for the hydrogenation of organic hydrogenatable compounds or for formate degradation.
Method for preparing alcohol compound through hydrogenation of carbonyl-containing compound
-
Paragraph 0059-0061, (2021/07/10)
The invention provides a method for preparing an alcohol compound through hydrogenation of a carbonyl-containing compound, the method comprises the following steps: firstly, contacting the carbonyl-containing compound with a nickel catalyst precursor to obtain a nickel-containing solution, then carrying out a contact reaction on the nickel-containing solution and hydrogen, converting the contained nickel into a nickel catalyst, and carrying out in-situ catalysis on the hydrogenation reaction of the carbonyl-containing compound, and obtaining the alcohol compound. According to the preparation method provided by the invention, the preparation of the nickel catalyst and the hydrogenation reaction of the carbonyl-containing compound are carried out in the same technological process for the first time, the prepared nickel catalyst is good in catalytic activity and long in service life, and the alcohol compound prepared by in-situ catalysis is high in yield and good in selectivity, so that the production cost of the alcohol compound can be remarkably reduced, the production efficiency is improved, and the method is particularly suitable for large-scale industrial production.
PROCESS FOR PREPARING AN ALCOHOL FROM HYDROCARBONS
-
Paragraph 0074, (2020/12/25)
The invention provides a process for preparing an alcohol by hydrogenating an ester which is obtained by alkoxycarbonylating a C2 to C20 hydrocarbon having at least one multiple bond, preferably having at least one olefinic double bond, in which the homogeneous catalyst system used is separated from the product mixture by means of membrane separation. In a development of the present invention, the ester thus formed is converted to another ester by transesterification and then hydrogenated.
Preparation method of isononyl alcohol (by machine translation)
-
Paragraph 0029-0031, (2020/12/10)
The invention discloses a preparation method of isononol, which comprises 1) reacting isooctenyl and formaldehyde to obtain isononol; 2) reacting the isononol obtained in step 1) in the presence of a hydrogenation catalyst to obtain isononol; wherein, Step 1) The isononyl alcohol hydrogenation reaction condition comprises 160 - 250 °C. 1 - 1000:1, reaction time 5.0-10 .0 mpa and reaction space velocity. 100 - 400. The method comprises the following reaction conditions: No.1 - 5h. The reaction temperature is from 2 times/min, and the reaction pressure is 300. The reaction 0.2 - 1.0h space is 50 - 120 °C 2.0 - 6.0 mpa. -1 The preparation method of isononyl alcohol provided by the invention is mild in reaction condition, small in reaction heat, low in catalyst price, free of corrosion equipment, environmentally friendly, insoluble in organic matters, simple in equipment, convenient to operate and low in investment cost. (by machine translation)
Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I
Amatuni, Alexander,Shuster, Anton,Adibekian, Alexander,Renata, Hans
, p. 1318 - 18,1326 (2020/09/02)
Amatuni et al. established a concise chemoenzymatic synthesis of cepafungin I. The route enabled access to a chemoproteomic probe, revealing high selectivity for proteasome subunits β5/2. Potent inhibition was associated with the macrocyclic hydroxyl group and lipid tail. Cepafungin I exhibited similar mode of action with the clinical drug bortezomib. The natural product cepafungin I was recently reported to be one of the most potent covalent inhibitors of the 20S proteasome core particle through a series of in vitro activity assays. Here, we report a short chemoenzymatic total synthesis of cepafungin I featuring the use of a regioselective enzymatic oxidation to prepare a key hydroxylated amino acid building block in a scalable fashion. The strategy developed herein enabled access to a chemoproteomic probe, which in turn revealed the exceptional selectivity and potency of cepafungin I toward the β2 and β5 subunits of the proteasome. Further structure-activity relationship studies suggest the key role of the hydroxyl group in the macrocycle and the identity of the lipid tail in modulating the potency of this natural product family. This study lays the groundwork for further medicinal chemistry exploration to fully realize the anticancer potential of cepafungin I.
CATALYST AND PROCESS FOR HYDROGENATING AROMATICS
-
, (2012/12/13)
The present invention relates to an eggshell catalyst comprising an active metal selected from the group consisting of ruthenium, rhodium, palladium, platinum and mixtures thereof, applied to a support material comprising silicon dioxide, wherein the pore volume of the support material is 0.6 to 1.0 ml/g, determined by Hg porosimetry, the BET surface area is 280 to 500 m2/g, and at least 90% of the pores present have a diameter of 6 to 12 nm, to a process for preparing this eggshell catalyst, to a process for hydrogenating an organic compound which comprises at least one hydrogenatable group using the eggshell catalyst, and to the use of the eggshell catalyst for hydrogenating an organic compound.
Group of anti-cancer compounds with specific structure and their production method
-
Page/Page column 26, (2010/11/23)
Compounds containing a specific branched chain end terminal group, which is isopropyl, sec.-butyl, or tert.-butyl; a polar leading group; and long-chain aliphatic, non-cyclic, saturated or unsaturated, hydrocarbon group linking them; and having anti-cancer and immune boosting activity.
Influence of terminal branching on the transdermal permeation-enhancing activity in fatty alcohols and acids
Klimentova, Jana,Kosak, Petr,Vavrova, Katerina,Holas, Tomas,Hrabalek, Alexandr
, p. 7681 - 7687 (2007/10/03)
In order to investigate the effect of terminal chain branching in the skin permeation enhancers, seven alcohols and seven acids with the chain length of 8-12 carbons and terminal methyl or ethyl branching were prepared. Their transdermal permeation-enhancing activities were evaluated in vitro using theophylline as a model permeant and porcine skin, and compared to those of the linear standards. Terminal methyl branching increased the enhancing activity only in 12C acid, no effect was seen in the shorter ones. Terminal ethyl however produced a significant increase in activity. In the alcohols, the branching was likely to change the mode of action, due to a different relationship between the activity and the chain length.
Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
-
Page 12, (2010/02/05)
Compounds for treating abuse of nicotinic receptor agonists, addiction to psychostimulant drugs, addiction to opiates, addiction to alcohol, addiction to tobacco products, addiction to nicotine, schizophrenia and related diseases, depression and related conditions, Alzheimer's disease, Parkinson's disease, irritable bowel syndrome, and colitis. The compounds competitively inhibit central nervous system acting nicotinic receptor agonists and act at the putative α3β2* and α4β2 neuronal nicotinic receptors in the central nervous system.
